Arvinas (ARVN) Free Cash Flow Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Free Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 31.57% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 58.53% |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | 49.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49.79% |
| Mar 31, 2026 | 21.05% |
| Dec 31, 2025 | 63.74% |
| Sep 30, 2025 | 54.00% |
| Jun 30, 2025 | -294.76% |
| Mar 31, 2025 | 8.50% |
| Dec 31, 2024 | -1.44% |
| Sep 30, 2024 | -49.83% |
| Jun 30, 2024 | 155.54% |
| Mar 31, 2024 | -5.74% |
| Dec 31, 2023 | -15.08% |
| Sep 30, 2023 | -24.85% |
| Jun 30, 2023 | -11.62% |
| Mar 31, 2023 | -55.91% |
| Dec 31, 2022 | -92.29% |
| Sep 30, 2022 | -110.11% |
| Jun 30, 2022 | -67.01% |
| Mar 31, 2022 | -48.00% |
| Dec 31, 2021 | -22.19% |
| Sep 30, 2021 | 2,959.11% |